Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study
In this large real-world cohort of patients with mCRC, FTD-TPI + bevacizumab was associated with improved PFS and DCR compared with FTD-TPI or regorafenib, with consistent benefit across most molecular subgroups, including KRAS<sup>G12</sup> mutations.
Authors
- S.A. Suppe
- J.M. Riedl
- A. Gerger
- A. Amann
- L. Weiss
- F. Moik
- R. Schaberl-Moser
- H. Taghizadeh
- M. Abdel Hamid
- P. Reimann
- A. Seeber
- S.M. Kostmann
- K.C. Zimmer
- T. Winder
- C. Bachleitner
- R. Greil
- P.J. Jost
- L. Wagner
- B. Doleschal
- D. Wolf
- F. Huemer
- H. Rumpold
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Medical University of Graz (AT)
- Paracelsus Medical University (AT)
- Landeskrankenhaus Feldkirch (AT)
- Universitätsklinikum St. Pölten (AT)
- BioTechMed-Graz (AT)
- Krankenhaus der Elisabethinen (AT)
- Austrian Breast & Colorectal Cancer Study Group (AT)
- University Hospital Innsbruck (AT)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106907
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00